If, under national legislation, the rights laid down in Article 3(2) are subject to a limitationperiod, that period shall not expire within a period of two years from the time of delivery.
Novartis argues that even if the 180-day limitation stands, that period should run from Jan. 21, the day the USPTO said it would not challenge the Wyeth decision, or the date of the decision itself.